|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.070 USD | -4.20% |
|
+27.16% | +221.36% |
| Dec. 09 | Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants | RE |
| Dec. 08 | Immix Biopharma Prices $100 Million Offering | MT |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Profitability | ||||||
Return on Assets | -23.5 | -9.02 | -31.04 | -57.92 | -66.11 | |
Return on Total Capital | 2.23K | -9.71 | -32.93 | -68.71 | -92.84 | |
Return On Equity % | 24.46 | -367.8 | -52.84 | -106.22 | -147.33 | |
Return on Common Equity | 24.46 | -367.8 | -52.84 | -104.35 | -145.76 | |
Short Term Liquidity | ||||||
Current Ratio | 0.13 | 90.01 | 11.7 | 5.32 | 2.33 | |
Quick Ratio | 0.13 | 87.46 | 10.75 | 5.02 | 2.26 | |
Operating Cash Flow to Current Liabilities | -0.08 | -7.87 | -5.82 | -3.06 | -1.68 | |
Long Term Solvency | ||||||
Total Debt/Equity | -89.69 | 0.28 | - | - | 8.11 | |
Total Debt / Total Capital | -870.36 | 0.28 | - | - | 7.5 | |
LT Debt/Equity | - | - | - | - | 7.62 | |
Long-Term Debt / Total Capital | - | - | - | - | 7.05 | |
Total Liabilities / Total Assets | 743.67 | 1.11 | 11.73 | 18.68 | 42.26 | |
EBIT / Interest Expense | -3.05 | -7.52 | -16.54K | - | - | |
EBITDA / Interest Expense | -3.02 | -7.5 | -16.53K | - | - | |
(EBITDA - Capex) / Interest Expense | -3.02 | -7.51 | -16.53K | - | - | |
Total Debt / EBITDA | -13.29 | -0.04 | - | - | -0.05 | |
Net Debt / EBITDA | -12.02 | 13.04 | 1.64 | 1.09 | 0.74 | |
Total Debt / (EBITDA - Capex) | -13.29 | -0.04 | - | - | -0.05 | |
Net Debt / (EBITDA - Capex) | -12.02 | 13.03 | 1.64 | 1.08 | 0.7 | |
Growth Over Prior Year | ||||||
EBITDA, 1 Yr. Growth % | -63.34 | 198.88 | 508.86 | 96.37 | 40.32 | |
EBITA, 1 Yr. Growth % | -63.11 | 197.9 | 507.9 | 96.39 | 40.48 | |
EBIT, 1 Yr. Growth % | -63.11 | 197.9 | 507.9 | 96.39 | 40.48 | |
Earnings From Cont. Operations, 1 Yr. Growth % | 3.29 | 2.02K | -66.25 | 89.5 | 39.13 | |
Net Income, 1 Yr. Growth % | 3.29 | 2.02K | -66.25 | 87.44 | 40.11 | |
Normalized Net Income, 1 Yr. Growth % | 3.67 | 2.05K | -66.16 | 86.12 | 40.68 | |
Diluted EPS Before Extra, 1 Yr. Growth % | 3.29 | 1.85K | -91.07 | 50.11 | -14.1 | |
Net Property, Plant and Equip., 1 Yr. Growth % | -23.97 | -22.63 | -37.49 | 1.31K | 5.34K | |
Total Assets, 1 Yr. Growth % | -24.69 | 3.27K | -18.05 | 33.65 | 15.17 | |
Tangible Book Value, 1 Yr. Growth % | 25.36 | -480.29 | -26.85 | 24.66 | -19.23 | |
Common Equity, 1 Yr. Growth % | 25.36 | -480.29 | -26.85 | 24.66 | -19.23 | |
Cash From Operations, 1 Yr. Growth % | -48.78 | 292.72 | 366.13 | 53.5 | 28.35 | |
Capital Expenditures, 1 Yr. Growth % | - | - | - | - | 2.16K | |
Levered Free Cash Flow, 1 Yr. Growth % | - | -632.49 | 105.43 | 37.8 | 27.18 | |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | -546.48 | 110.87 | 37.81 | 27.18 | |
Compound Annual Growth Rate Over Two Years | ||||||
EBITDA, 2 Yr. CAGR % | - | 26.64 | 326.59 | 245.78 | 66 | |
EBITA, 2 Yr. CAGR % | - | 26.68 | 325.55 | 245.52 | 66.1 | |
EBIT, 2 Yr. CAGR % | - | 26.68 | 325.55 | 245.52 | 66.1 | |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | 400.65 | 167.76 | -20.03 | 62.38 | |
Net Income, 2 Yr. CAGR % | - | 400.65 | 167.76 | -20.46 | 62.06 | |
Normalized Net Income, 2 Yr. CAGR % | - | 405.07 | 169.66 | -20.64 | 61.81 | |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | 379.94 | 32 | -63.4 | 13.55 | |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | -23.31 | -30.46 | 196.84 | 2.67K | |
Total Assets, 2 Yr. CAGR % | - | 339.24 | 425.63 | 4.65 | 24.07 | |
Tangible Book Value, 2 Yr. CAGR % | - | 122.12 | 66.79 | -4.51 | 0.35 | |
Common Equity, 2 Yr. CAGR % | - | 122.12 | 66.79 | -4.51 | 0.35 | |
Cash From Operations, 2 Yr. CAGR % | - | 41.83 | 327.85 | 167.49 | 40.36 | |
Capital Expenditures, 2 Yr. CAGR % | - | -66.87 | - | 705.91 | - | |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | 230.74 | 68.25 | 32.38 | |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | 206.83 | 70.47 | 32.39 | |
Compound Annual Growth Rate Over Three Years | ||||||
EBITDA, 3 Yr. CAGR % | - | - | 113.75 | 229.38 | 156 | |
EBITA, 3 Yr. CAGR % | - | - | 113.67 | 228.86 | 155.97 | |
EBIT, 3 Yr. CAGR % | - | - | 113.67 | 228.86 | 155.97 | |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | 103.76 | 138.62 | -3.81 | |
Net Income, 3 Yr. CAGR % | - | - | 103.76 | 137.75 | -3.94 | |
Normalized Net Income, 3 Yr. CAGR % | - | - | 105.13 | 138.31 | -3.96 | |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | 27.16 | 37.78 | -51.36 | |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | -28.36 | 89.61 | 682.59 | |
Total Assets, 3 Yr. CAGR % | - | - | 150.98 | 233 | 8.05 | |
Tangible Book Value, 3 Yr. CAGR % | - | - | 53.39 | 51.36 | -9.69 | |
Common Equity, 3 Yr. CAGR % | - | - | 53.39 | 51.36 | -9.69 | |
Cash From Operations, 3 Yr. CAGR % | - | - | 110.87 | 204.02 | 109.41 | |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | - | 1.04K | |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 147.02 | 53.26 | |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | 134.98 | 54.61 | |
Compound Annual Growth Rate Over Five Years | ||||||
EBITDA, 5 Yr. CAGR % | - | - | - | - | 93.19 | |
EBITA, 5 Yr. CAGR % | - | - | - | - | 93.19 | |
EBIT, 5 Yr. CAGR % | - | - | - | - | 93.19 | |
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | - | 86.07 | |
Net Income, 5 Yr. CAGR % | - | - | - | - | 85.93 | |
Normalized Net Income, 5 Yr. CAGR % | - | - | - | - | 86.56 | |
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | - | 21.53 | |
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | - | 209.05 | |
Total Assets, 5 Yr. CAGR % | - | - | - | - | 89.34 | |
Tangible Book Value, 5 Yr. CAGR % | - | - | - | - | 29.44 | |
Common Equity, 5 Yr. CAGR % | - | - | - | - | 29.44 | |
Cash From Operations, 5 Yr. CAGR % | - | - | - | - | 79.19 | |
Capital Expenditures, 5 Yr. CAGR % | - | - | - | - | 176.34 |
- Stock Market
- Equities
- IMMX Stock
- Financials Immix Biopharma, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















